Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | GABRP | O00591 | 3/20 | 0.36 |
| ▸ | GABRD | O14764 | 3/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.36 |
| ▸ | GABRE | P78334 | 3/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180138 | 0.86 | SRC (0.45) | SRCKDRGABRPGABRDGABRA1 | |
| SCHEMBL6208048 | 0.86 | KDR (0.57) | SRCKDRGABRPGABRDGABRA1 | |
| SCHEMBL6402245 | 0.80 | EPHB4 (0.50) | SRCKDRRIPK2PLK4ROCK2 | |
| SCHEMBL2349535 | 0.77 | SRC (0.40) | SRCKDRL3MBTL1RIPK2RET | |
| SCHEMBL13330183 | 0.74 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL13306144 | 0.74 | — | — | |
| SCHEMBL20334823 | 0.70 | RET (0.38) | SRCKDRCYP3A4RIPK2RET | |
| SCHEMBL20334789 | 0.68 | RET (0.52) | SRCCYP3A4RET | |
| SCHEMBL12449760 | 0.67 | GABRP (0.37) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1703067 | 0.66 | ICAM1 (0.47) | CYP3A4MAP4K4MKNK2ICAM1SELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035349-A1 | PYRAZOLOPYRIMIDINONE KINASE INHIBITOR | AGENNIX AG (DE) | 2013-02-07 | — | — | US | disclosed |
| US-20130035349-A1 | PYRAZOLOPYRIMIDINONE KINASE INHIBITOR | AGENNIX AG (DE) | 2013-02-07 | — | — | US | disclosed |
| US-8304418-B2 | Pyrazolopyrimidinone kinase inhibitor | AGENNIX AG (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304418-B2 | Pyrazolopyrimidinone kinase inhibitor | AGENNIX AG (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20100160350-A1 | PYRAZOLOPYRIMIDINONE KINASE INHIBITOR | AGENNIX AG (DE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160350-A1 | PYRAZOLOPYRIMIDINONE KINASE INHIBITOR | AGENNIX AG (DE) | 2010-06-24 | — | — | US | disclosed |
| EP-2019101-A1 | Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor | GPC Biotech AG (DE) | 2009-01-28 | — | — | EP | disclosed |
| WO-2008145678-A1 | PYRAZOLOPYRIMIDINONE KINASE INHIBITOR | GPC BIOTECH AG (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035349-A1 | PYRAZOLOPYRIMIDINONE KINASE INHIBITOR | MAP3K19, MAP3K4, MAP3K1 | SRC 360/4885KDR 1079/4885GABRP 2615/4885 |
| US-20100160350-A1 | PYRAZOLOPYRIMIDINONE KINASE INHIBITOR | MAP3K19, MAP3K4, MAP3K1 | SRC 360/4885KDR 1079/4885GABRP 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.